GlaxoSmithKline (GSK) is cutting the price charged for its pneumococcal vaccine when given to refugees, following complaints about the product’s “exorbitant” cost by medical charity Médecins Sans Frontiéres (MSF).
For seven years, MSF has been in discussions with GSK and Pfizer, the only two manufacturers producing the pneumonia vaccine, for access to a more affordable price.
GSK said it would provide Synflorix at a discounted price of $3.05 per dose to recognised civil society organisations.
The price, which GSK says is intended solely to support refugee populations, has previously been available only to the world’s poorest countries.
MSF now hopes that Pfizer will match GSK’s offer, and that both companies will additionally reduce the price of the vaccine for governments of developing countries.